Sitagliptin Performs Well in Early Studies : Novel compound significantly reduces glucose and is well tolerated in patients with type 2 diabetes.

There were no clinically significant treatment-related trends in clinical or laboratory adverse events or test abnormalities, nor any differences in vital signs or other physical findings. One hypoglycemic event occurred in each sitagliptin group, with none reported in the placebo group.

Phase III trials of sitagliptin are underway, according to a Merck statement.